Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.24 and traded as low as $0.2296. Northwest Biotherapeutics shares last traded at $0.2327, with a volume of 2,694,391 shares.
Northwest Biotherapeutics Price Performance
The business has a fifty day simple moving average of $0.21 and a 200 day simple moving average of $0.24. The firm has a market cap of $384.94 million, a price-to-earnings ratio of -0.01 and a beta of -0.74.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
